Cargando…

Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy

Transarterial chemoembolization (TACE) is the first-line treatment for unresectable intermediate-stage hepatocellular carcinoma (HCC). It is of high clinical significance to explore the synergistic effect of TACE with antiangiogenic inhibitors and the molecular mechanisms involved. This study determ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Jing, Feng, Ji, Wu, Yong, Dai, Hui-Qi, Zhu, Guang-Zhi, Chen, Pan-Hong, Wang, Li-Ming, Lu, Guang, Liao, Xi-Wen, Lu, Pei-Zhi, Su, Wen-Jing, Hooi, Shing Chuan, Ye, Xin-Pin, Shen, Han-Ming, Peng, Tao, Lu, Guo-Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723179/ https://www.ncbi.nlm.nih.gov/pubmed/36385558 http://dx.doi.org/10.1038/s12276-022-00878-x

Ejemplares similares

The Long and the Short of PTEN in the Regulation of Mitophagy
por: Wang, Liming, et al.
Publicado: (2020)

E3 Ubiquitin Ligase Siah-1 is Down-regulated and Fails to Target Natural HBx Truncates for Degradation in Hepatocellular Carcinoma
por: Zhao, Jing, et al.
Publicado: (2016)

Mitochondrial Fission and Mitophagy Reciprocally Orchestrate Cardiac Fibroblasts Activation
por: Gao, Qing-Yuan, et al.
Publicado: (2021)

Suppression of Natural Killer Cells by Sorafenib Contributes to Prometastatic Effects in Hepatocellular Carcinoma
por: Zhang, Qiang-Bo, et al.
Publicado: (2013)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Liver X Receptor Agonism Sensitizes a Subset of Hepatocellular Carcinoma to Sorafenib by Dual-Inhibiting MET and EGFR
por: Shao, Weiqing, et al.
Publicado: (2019)

Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib
por: Meng, Xiao-Chun, et al.
Publicado: (2018)

Investigating the Molecular Basis of Siah1 and Siah2 E3 Ubiquitin Ligase Substrate Specificity
por: Gopalsamy, Anupriya, et al.
Publicado: (2014)

The PARP1-Siah1 Axis Controls HIV-1 Transcription and Expression of Siah1 Substrates
por: Yu, Dan, et al.
Publicado: (2018)

Mitochondrial Fission and Mitophagy Coordinately Restrict High Glucose Toxicity in Cardiomyocytes
por: Kobayashi, Satoru, et al.
Publicado: (2020)

SIAH2-mediated and organ-specific restriction of HO-1 expression by a dual mechanism
por: Chillappagari, Shashipavan, et al.
Publicado: (2020)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
por: Zeng, Zhi, et al.
Publicado: (2021)

Aspirin Minimized the Pro-Metastasis Effect of Sorafenib and Improved Survival by Up-Regulating HTATIP2 in Hepatocellular Carcinoma
por: Lu, Lu, et al.
Publicado: (2013)

Sorafenib Combined with Cryoablation to Treat Unresectable Hepatocellular Carcinoma
por: Ni, Hong, et al.
Publicado: (2011)

CYP2C8 Suppress Proliferation, Migration, Invasion and Sorafenib Resistance of Hepatocellular Carcinoma via PI3K/Akt/p27(kip1) Axis
por: Zhou, Xin, et al.
Publicado: (2021)

Phosphoglucomutase 1 inhibits hepatocellular carcinoma progression by regulating glucose trafficking
por: Jin, Guang-Zhi, et al.
Publicado: (2018)

Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagy
por: Zhou, Sining, et al.
Publicado: (2023)

Simultaneous multitarget radiotherapy using helical tomotherapy and its combination with sorafenib for pulmonary metastases from hepatocellular carcinoma
por: Sun, Taiwei, et al.
Publicado: (2016)

Serial changes of clinical parameters in a patient with advanced hepatocellular carcinoma with portal vein thrombosis achieving complete response after treatment with sorafenib
por: Kee, Kwong-Ming, et al.
Publicado: (2014)

Anterior gradient 2 induces resistance to sorafenib via endoplasmic reticulum stress regulation in hepatocellular carcinoma
por: Tsai, Hung-Wen, et al.
Publicado: (2023)

Effects of lifestyle interventions on glucose regulation and diabetes risk in adults with impaired glucose tolerance or prediabetes: a meta-analysis
por: Jiang, Qiang, et al.
Publicado: (2022)

Mitophagy promotes sorafenib resistance through hypoxia-inducible ATAD3A dependent Axis
por: Wu, Hong, et al.
Publicado: (2020)

Cathepsin K promotes the proliferation of hepatocellular carcinoma cells through induction of SIAH1 ubiquitination and degradation
por: Zhang, Chengming, et al.
Publicado: (2023)

Identification of Key Genes in Purine Metabolism as Prognostic Biomarker for Hepatocellular Carcinoma
por: Su, Wen-Jing, et al.
Publicado: (2021)

Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus
por: Zhang, Zi-Han, et al.
Publicado: (2017)

Effects of hyperbaric oxygen therapy on neuropathic pain via mitophagy in microglia
por: Han, Guang, et al.
Publicado: (2017)

WIPI2 positively regulates mitophagy by promoting mitochondrial recruitment of VCP
por: Lu, Guang, et al.
Publicado: (2022)

The clinical effect and relevant mechanism of combined sorafenib and radiofrequency ablation in the treatment of early small hepatocellular carcinoma
por: Yan, Shi-Yan, et al.
Publicado: (2016)

STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib
por: Zheng, Yahui, et al.
Publicado: (2021)

Resection vs. Sorafenib for Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Real World, Propensity Score Matched Analytic Study
por: Mei, Jie, et al.
Publicado: (2020)

Comparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination Therapy
por: Zheng, Jian-feng, et al.
Publicado: (2015)

Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study
por: Zhao, Jian-Dong, et al.
Publicado: (2010)

In silico and in vitro identification of inhibitory activities of sorafenib on histone deacetylases in hepatocellular carcinoma cells
por: Liu, Tsang-Pai, et al.
Publicado: (2017)

Sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype?
por: Shing, Kit, et al.
Publicado: (2020)

Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma
por: Huang, Song-Fong, et al.
Publicado: (2022)

SIAH1 reverses chemoresistance in epithelial ovarian cancer via ubiquitination of YBX-1
por: Gao, Wujiang, et al.
Publicado: (2022)

SIAH1-mediated RPS3 ubiquitination contributes to chemosensitivity in epithelial ovarian cancer
por: Chen, Lu, et al.
Publicado: (2022)

Canonical WNT Signaling Activated by WNT7B Contributes to L-HBs-Mediated Sorafenib Resistance in Hepatocellular Carcinoma by Inhibiting Mitophagy
por: Liu, Li-Juan, et al.
Publicado: (2022)

Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma
por: Zhao, Yang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_p90bah0b7rk1vo7h8jc1aujn9i